Key result
Pharmacotherapeutic options for venous thromboembolism prophylaxis and treatment are reviewed according to South African Essential Medicines List and Standard Treatment Guidelines.
Why the study?
Venous thromboembolism remains a significant cause of preventable morbidity and mortality globally, with notable under-treatment in South Africa.
Answers are grounded in this paper and cite their sources.
This review outlines the pharmacokinetic, pharmacodynamic, and clinical aspects of pharmacotherapeutic options for venous thromboembolism prophylaxis and treatment in accordance with South African Standard Treatment Guidelines.
Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, continues to be a significant cause of preventable morbidity and mortality globally, with notable under-treatment in South Africa. This review explores the pathophysiology, prevention, and treatment of venous thromboembolism, focusing on current practices in South Africa. Current pharmacotherapeutic options, such as unfractionated heparin, low-molecular-weight heparins, warfarin, direct oral anticoagulants, fondaparinux, and fibrinolytic agents, are discussed from a pharmacokinetic and pharmacodynamic view, with emphasis on their clinical use as per the South African Essential Medicines List and Standard Treatment Guidelines.
No takes yet. Share an insight, caveat, or question.
Badenhorst et al. (2026) conducted a review in Venous thromboembolism (deep vein thrombosis and pulmonary embolism). Anticoagulants and fibrinolytic agents (UFH, LMWH, warfarin, DOACs, fondaparinux) was evaluated. Pharmacotherapeutic options for venous thromboembolism prophylaxis and treatment are reviewed according to South African Essential Medicines List and Standard Treatment Guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: